id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-6530-0009,FDA,FDA-2017-D-6530,Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products; Draft Guidance for Industry,Other,Guidance,2023-09-22T04:00:00Z,2023,9,2023-09-22T04:00:00Z,2023-12-22T04:59:59Z,2024-11-07T00:52:31Z,,1,0,0900006485fe5f92
FDA-2017-D-6530-0008,FDA,FDA-2017-D-6530,Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-09-22T04:00:00Z,2023,9,2023-09-22T04:00:00Z,,2023-09-22T14:54:46Z,2023-20592,0,0,0900006485fe5666
FDA-2017-D-6530-0002,FDA,FDA-2017-D-6530,Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-03-30T03:59:59Z,2024-11-07T01:15:37Z,,1,0,0900006482d7eb25
FDA-2017-D-6530-0001,FDA,FDA-2017-D-6530,Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,2018-03-30T03:59:59Z,2018-03-28T01:02:41Z,2017-28140,0,0,0900006482d832bd